- Khiron's first clinic outside of Bogota, supporting demand for the Company's
clinic services and expanding patient access to medical
cannabis
- Opening represents Khiron's fourth clinic in Colombia, enabling direct patient access in
Medellin – A region with more than
6 million residents
- Leverages the proven Zerenia model which to date has attracted
25% of patients from outside of Bogota
- Medellin clinic to open and
begin meeting patient needs in early December 2020
- Continues Khiron's satellite clinic expansion strategy, with
recently announced Mexican clinic
TORONTO, Dec. 1, 2020 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America and Europe, today announces the opening of its
first Zerenia clinic in Medellin,
Colombia´s second largest city with reach to over 6 million
residents in the region.
The Medellin clinic, with a
grand opening planned for December 8,
2020, supports Khiron´s goal of expanding regional access to
the Company's proven clinic services and medical cannabis products
for patients across the country, with a focus on in-person and
telehealth services in Colombia's
largest urban centres. The clinic is conveniently located in the
San Diego sector of the city,
minutes from downtown with access to public transit and walking
distance to major business and residential areas.
"We launched our Zerenia operations in Bogota in Q1 2020 and in Q2 our Dr. Zerenia
telehealth operations began. The clinic data quickly showed that
more than 25% of patients were accessing our telehealth services
from outside of Bogota. Once
proven successful, Khiron will continue to expand its regional
presence, in Colombia and beyond,"
comments Alvaro Torres, Khiron CEO
and Director.
The Zerenia Medellin clinic will be the first in the city,
expanding national access and improving the quality of life of
patients in the populous Antioquia region. The clinic will provide
face-to-face care and teleconsultation through the Doctor Zerenia
platform and physical consultation, connecting patients with
medical specialists trained in the ethical, safe and responsible
prescription of cannabis-based medications, and in the
comprehensive treatment of pathologies such as chronic pain,
anxiety, insomnia, depression, headache, epilepsy and
Parkinson's.
About Khiron Life Sciences Corp.
Khiron is a vertically integrated medical and CPG cannabis
company with core operations in Latin
America, and operational activity in Europe and North
America. Khiron is the leading cannabis company in
Colombia and the first company
licensed in Colombia for the
cultivation, production, domestic distribution and sales, and
international export of both low and high THC medical cannabis
products. The Company has filled medical cannabis prescriptions in
Peru and has a presence in
Mexico, Uruguay, UK, Spain and also in Germany, where it is positioned to begin sales
of medical cannabis.
Leveraging its first-mover advantage and patient-oriented
approach, Khiron combines global scientific expertise, product
innovation, agricultural infrastructure, wholly-owned medical
clinics, and online doctor education programs to drive prescription
and brand loyalty to address priority medical conditions. Its
Wellbeing unit launched the first branded CBD skincare brand in
Colombia, with KuidaTM
now marketed in multiple jurisdictions in Latin America, the US and UK. The Company is
led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
@khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-to-open-new-regional-zerenia-clinic-in-medellin-colombia-301182137.html
SOURCE Khiron Life Sciences Corp.